Daiichi Sankyo, which has struggled financially since losing exclusivity for its blood pressure drug Benicar, is again swinging the job-cutting ax in the U.S., cutting 280 jobs from its commercial operations.
The Japanese drugmaker last week said the jobs are being eliminated from various locations in the U.S., as it streamlines its business to fit its current U.S. portfolio and “prepare for its upcoming oncology pipeline.”
“Our priorities are to bring spending in line with revenue, shift resources to maximize Injectafer and our abuse-deterrent pain treatments, and prepare for exciting potential new treatments for patients with cancer being developed by our R&D organization,” Ken Keller, president of administrative and commercial for Daiichi Sankyo, said in a statement.
The cuts follow a downsizing of about 1,200 employees in the U.S. which culminated with the company melding its U.S. R&D and commercial operations in a new facility in Basking Ridge, New Jersey, in April 2016. About 700 employees from its former U.S. headquarters in Parsippany, New Jersey, and R&D in Edison, New Jersey, made that move.
Daiichi also closed a 170-person R&D facility in India last year and month later shuttered another in Japan with 150 employees.
Daiichi has been trying to remake itself since before losing patent protection on its $2.6 billion seller Benicar in 2016. It has been shifting away from primary care meds and toward specialty drugs such as its clot-fighting pill Savaysa, and Movantik, a constipation drug it markets with AstraZeneca.
Last year it also had to lay out $300 million to settle about 2,300 lawsuits tied to side effects of the blood pressure medication and several related drugs.
By Eric Palmer
Source: Fierce Pharma
The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has introduced several new measures to make it easier to run clinical trials in the country, marking the first time in 20 years the regulatory body has made such an overhaul.
Diabetes drugmaker Novo Nordisk is partnering with Dewpoint Therapeutics in a deal aimed at uncovering new treatments for insulin resistance by targeting cellular droplets known as biomolecular condensates. Dewpoint will receive $55 million upfront from Novo, which plans to develop small molecule drugs against targets discovered using Dewpoint’s technology.
Sanofi has secured approval for Dupixent (dupilumab) from the European Commission (EC) to treat severe atopic dermatitis in children aged six months to five years, who are systemic therapy candidates, in the European Union (EU). This approval makes Dupixent the first and only medicine available in the US and Europe for the treatment of such young children.
